Implantable Bio-Artificial Pancreas (iBAP)

项目摘要 大约有300万美国人和全世界大约2400万人受到1型糖尿病的影响 （T1D）。胰岛素注射后血糖监测，同种异体全器官胰腺移植， 同种异体胰岛移植是T1D最常见的治疗方法。这些治疗可以达到 许多患者的血糖控制，但导致严重的并发症。生物人工胰腺是一种很有前途的 治疗T1D，因为它含有功能性胰岛。然而，以前试图开发一种生物人工 装置受到质量传递不足和β细胞供应有限的严重限制。舒沃医生 罗伊（PI）开发了硅纳米孔膜（SNM），以实现高效血液超滤 同时选择性地保留生物人工肾项目的特定溶质，该项目的成功是 可直接转移到可植入的生物人工胰腺（iBAP）。超高渗透率 SNM的特性将使适当的质量传输（特别是氧气，葡萄糖和胰岛素） 以实现最佳的β细胞性能，而SNM的超选择性孔特性使 前所未有的免疫隔离此外，iBAP将利用人类胚胎干细胞衍生的全功能 为iBAP开发和临床转化提供无限供应的β细胞。

Project Summary Approximately 3 million Americans and around 24 million people worldwide are affected by Type 1 Diabetes (T1D). Glucose monitoring followed by insulin injection, allogeneic whole organ pancreas transplantation, and allogeneic islet transplantation are the most common treatments for T1D. These treatments can achieve glycemic control for many patients but result in serious complications. A bioartificial pancreas is a promising treatment for T1D because it contains functional islets. However, previous attempts to develop a bioartificial device have been severely limited by insufficient mass transfer and a limited supply of beta cells. Dr. Shuvo Roy (PI) has developed silicon nanopore membranes (SNM) to achieve high-efficiency blood ultrafiltration while selectively retaining specific solutes for the Bioartificial Kidney project and this project's successes are directly transferrable to the implantable bioartificial pancreas (the iBAP). The ultra-high hydraulic permeability characteristic of the SNM will enable appropriate mass transport (especially oxygen, glucose, and insulin) within to achieve optimal beta cell performance, while the ultra-selective pore characteristic of the SNM enable unprecedented immunoisolation. Also the iBAP will utilize a human embryonic stem cell derived fully functional beta cell that provides and unlimited supply of beta cells for iBAP development and clinical translation.